Discovery of putative dual inhibitor of tubulin and egfr by phenotypic approach on lassbio-1586 homologs

HIGHLIGHTS

• who: Gisele Barbosa et al. from the Universidade Federal do Rio Janeiro, Universidade Federal do Rio Janeiro, Rio Janeiro, RJ, Brazil have published the article: Discovery of Putative Dual Inhibitor of Tubulin and EGFR by Phenotypic Approach on LASSBio-1586 Homologs, in the Journal: Pharmaceuticals 2022, 15, x FOR PEER REVIEW of /2022/
• what: To elucidate the cellular mechanism of action of LASSBio-1586 (2, 10 u00b5M), LASSBio-1735 (3, 0.5 u00b5M), LASSBio-2070 (10, 4.5 u00b5M), and LASSBio-2074 (11, 20 u00b5M), first identified as antimitotic agents , the authors performed immunofluorescence studies . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.